LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akcijų sąrašas・SCYNEXIS Inc

SCYNEXIS Inc

Uždarymo kaina

4.77 3.47

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.59

Max

4.95

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-34M -21M
Pelnas, tenkantis vienai akcijai	-0.418
Pelno marža	65.741
Darbuotojai	18
EBITDA	-29M -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+473.77% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	53M
Ankstesnė atidarymo kaina	1.3
Ankstesnė uždarymo kaina	4.77

SCYNEXIS Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-04 21:51; UTC

Pagrindinės rinkos jėgos

Merlin Shares Rally After Defense Department's Design Review Wraps

2026-06-04 23:46; UTC

Rinkos pokalbiai

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

2026-06-04 23:44; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-06-04 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

2026-06-04 23:41; UTC

Įsigijimai, susijungimai, perėmimai

Energy Resources of Australia to Enter Trading Halt

2026-06-04 23:34; UTC

Rinkos pokalbiai

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-04 23:08; UTC

Rinkos pokalbiai

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

2026-06-04 22:41; UTC

Rinkos pokalbiai

Australia Shares Set to Rise at the Open -- Market Talk

2026-06-04 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-04 20:44; UTC

Įsigijimai, susijungimai, perėmimai

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

2026-06-04 20:16; UTC

Rinkos pokalbiai

Mexican Demand Indicators Show Signs of Life -- Market Talk

2026-06-04 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

2026-06-04 19:46; UTC

Rinkos pokalbiai

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

2026-06-04 19:38; UTC

Rinkos pokalbiai

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

2026-06-04 19:30; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

2026-06-04 18:47; UTC

Įsigijimai, susijungimai, perėmimai

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

2026-06-04 18:38; UTC

Uždarbis

Money Quote: Tech Weakness in Context -- WSJ

2026-06-04 18:24; UTC

Uždarbis

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-04 17:09; UTC

Rinkos pokalbiai

Retest of $55k Seen Possible for Bitcoin -- Market Talk

2026-06-04 16:58; UTC

Uždarbis

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-04 16:46; UTC

Rinkos pokalbiai

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

2026-06-04 16:38; UTC

Uždarbis

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

2026-06-04 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-04 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-06-04 16:13; UTC

Rinkos pokalbiai

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

2026-06-04 16:11; UTC

Rinkos pokalbiai

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

2026-06-04 15:56; UTC

Rinkos pokalbiai

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Akcijų palyginimas

Kainos pokytis

SCYNEXIS Inc Prognozė

Kainos tikslas

By TipRanks

473.77% į viršų

12 mėnesių prognozė

Vidutinis 28 USD 473.77%

Aukščiausias 32 USD

Žemiausias 24 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines SCYNEXIS Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių SCYNEXIS Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.